Chardan Keeps Ocular Therapeutix Buy, $23 Target

Ocular Therapeutix has a mixed investment outlook: analysts are broadly positive, with a consensus “Moderate Buy” rating and an average price target of $25.29, while Chardan Capital reiterated its Buy rating and $23 target. The company’s latest reported quarter modestly beat expectations, posting revenue of $13.47 million and a loss of $0.35 per share. At the same time, valuation-focused analysis flags the stock as expensive, citing a price-to-sales ratio of 30.8 compared with roughly 4.5 for the pharmaceutical industry and 5.5 for peers. Investors are also weighing the company’s ongoing losses and the expected late-2026 NDA submission for its AXPAXLI treatment for wet age-related macular degeneration, which could shape future revenue prospects and spending needs.